Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Discontinuation of imatinib therapy after achieving a molecular response.

× No keyword cloud information.

78 in total

1. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.

Authors: Naoto Takahashi; Taiichi Kyo; Yasuhiro Maeda; Takashi Sugihara; Kensuke Usuki; Tatsuya Kawaguchi; Noriko Usui; Shinichiro Okamoto; Yokiko Ohe; Shigeki Ohtake; Kunio Kitamura; Masahide Yamamoto; Hirofumi Teshima; Toshiko Motoji; Toshiharu Tamaki; Kenichi Sawada; Kazuma Ohyashiki
Journal: Haematologica Date: 2011-12-16 Impact factor: 9.941

Review 2. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?

Authors: Meetu Agrawal; Ravin J Garg; Hagop Kantarjian; Jorge Cortes
Journal: Curr Oncol Rep Date: 2010-09 Impact factor: 5.075

3. Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.

Authors: Melda Comert; Yusuf Baran; Guray Saydam
Journal: Am J Blood Res Date: 2013-08-19

4. Fenretinide targets chronic myeloid leukemia stem/progenitor cells by regulation of redox signaling.

Authors: Yanzhi Du; Yuan Xia; Xiaoling Pan; Zi Chen; Aihua Wang; Kankan Wang; Junmin Li; Ji Zhang
Journal: Antioxid Redox Signal Date: 2013-10-24 Impact factor: 8.401

Review 5. The paradox of response and survival in cancer therapeutics.

Authors: Carol Ann Huff; William Matsui; B Douglas Smith; Richard J Jones
Journal: Blood Date: 2005-09-08 Impact factor: 22.113

Review 6. Applying the discovery of the Philadelphia chromosome.

Authors: Daniel W Sherbenou; Brian J Druker
Journal: J Clin Invest Date: 2007-08 Impact factor: 14.808

7. Imatinib spells BAD news for Bcr/abl-positive leukemias.

Authors: Scott H Kaufmann
Journal: Proc Natl Acad Sci U S A Date: 2006-09-26 Impact factor: 11.205

Review 8. Cancer stem cells: relevance to SCT.

Authors: T Lin; R J Jones; W Matsui
Journal: Bone Marrow Transplant Date: 2009-02-23 Impact factor: 5.483

9. Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia.

Authors: Shin Nakayama; Tokiko Nagamura-Inoue; Kazuaki Yokoyama; Nobuhiro Ohno; Jun Ooi; Satoshi Takahashi; Kaoru Uchimaru; Toru Iseki; Arinobu Tojo
Journal: Int J Hematol Date: 2007-10 Impact factor: 2.490

Review 10. Right on target: eradicating leukemic stem cells.

Authors: Daniela S Krause; Richard A Van Etten
Journal: Trends Mol Med Date: 2007-11-05 Impact factor: 11.951